MGC Pharmaceuticals is an emerging pharmaceutical company selling plant-derived, medicinal products in the UK, Ireland and Australia. Core marketed products are the food supplement, ArtemiC, promoted to help reduce COVID-19 symptoms, and medicinal cannabis products sold in Australia, UK and Ireland
EQS-News: MGC Pharmaceuticals Ltd MGC Pharmaceuticals delivers its largest-ever order 08.12.2022 / 14:46 CET/CEST The issuer is solely responsible for the content of this announcement. Contact DetailsProactiveProactive UK Ltd 3News Source: News Direct 08.12.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.Archive at -news.com Language:...
MGC Pharmaceuticals Ltd sells plant-derived, medicinal products in the UK, Ireland and Australia. Core marketed products are a food supplement, ArtemiC, to help overcome COVID-19 infection and medicinal cannabis products sold in Australia, UK and Ireland. A dramatic new initiative is the new medica
MCG Pharmaceuticals has reported some new data from preclinical laboratory studies done by its research collaborator, Slovenia's National Institute of Biology. The data highlights the possible use of cannabinoids in the treatment of glioblastoma multiforme (GBM), the aggressive, and most common, br
MCG sells medicinal cannabis products in the UK, Ireland, and Australia. Sales in the third quarter of the year to the end of March 2022 (Q3FY22) were A$550k, taking the fiscal year to date (YTD) total up to A$1.8mln. Sales of an anti-inflammatory, plant-based food supplement (ArtemiC) marketed for
MGC Pharma develops and markets medicines using compounds derived from cannabis and other plant-based sources. MCG recently reported its second-quarter (Q2) fiscal 2022 (FY22) cash flow and sales numbers. In this report, we also review the timing of the clinical trials programme. Our initiation rep
MGC Pharma is a bio-pharma company that develops and produces medicines using compounds derived from cannabis and other plant-based sources. Since our initiation report (June 22, 2021) the company has had several major news announcements, which have contributed to a 49% increase in the share price
Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR website. On 26 July 2021, Pengana International Equities Limited (PIA) announced a fully franked dividend of 1.35 cents per share for the June quarter. This represents an 8% increase on the March quarter dividend and takes the total dividends declared for FY21 of 5.1 cents per share, fully franked....
MGC Pharma is a bio-pharma company that develops and produces medicines using compounds derived from cannabis and other plant-based sources. The company has two separate product categories:The first category are ’phytotherapeautics’, health-promoting products derived from plant-based sources. There
Since beginning in earnest in August this year, 1,000 prescriptions for MGC’s phytocannabinoid products (CannEpil and MXP100) have been issued in Australia and the UK. Double the number of prescriptions were issued in October compared to September. Cash receipts for the quarter ending 30 September were A$413,000, with additional revenue of more than A$400,000 from recent sales expected to be received following the end of the quarter.
MGC Pharmaceuticals continues to put the building blocks in place for its seed-to-pharmacy medicinal cannabis business. It has received its first formal purchase orders for CannEpil in the UK, and has already received repeat orders from new distributors in Australia. It recently appointed distributors for Brazil, Germany, Austria and Switzerland. Its Phase II study of CogniCann in dementia is recruiting faster than expected. Preliminary approvals are in place for its Malta production hub, but it...
Key milestones for MGC Pharmaceuticals in 2019 include the launch of CannEpil sales in Australia, finalising contracts for the construction of a cannabis production and cultivation facility in Malta, and initiation of a Phase II study of CogniCann in dementia. The company has completed the sale of MGC Derma to CannaGlobal, which was announced in September. The transaction was restructured in November, which sees us reduce our valuation of the consideration to A$7.5m (vs A$12.5m). We adjust our v...
Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.